BGPartner advised the lead investor Novo Holdings and new investor LifeArc Ventures on all Swiss legal matters and the negotiations of GlycoEra’s financing round. The Swiss biotechnology company, closed a USD 130 million
Tags :Novo Holdings
Walder Wyss advised Danish life science investor Novo Holdings through its acquisition of American pharma multinational Catalent. Globally active in the fields of life sciences and healthcare, Novo Holdings acts as the only asset manager
BGPartner has advised OrbiMed and Novo Holdings on Swiss legal matters related to the USD 200 million Series A financing of Windward Bio Group, a Swiss-based clinical-stage drug development company, advised by Homburger. The financing round
Swiss biotech company Alentis Therapeutics has successfully closed a $181.4 million oversubscribed Series D financing round, supported by a syndicate of top-tier biotech investors. The financing will support the company to develop a deep pipeline of
